documents incorporated reference table c parts portions registrant 's annual report shareowners ii fiscal year part iii portions registrant 's proxy statement annual meeting shareowners table part table caption item c c business general segments business geographic areas consumer pharmaceutical medical devices diagnostics international raw materials patents trademarks seasonality competition research environment regulation properties legal proceedings submission matters vote security holders executive officers registrant part ii market registrant 's common equity related shareowner matters selected financial data management 's discussion analysis financial condition results operations quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accounting financial disclosure part iii directors executive officers registrant executive compensation security ownership certain beneficial owners management certain relationships related transactions part iv exhibits financial statement schedules reports form k signatures report independent accountants exhibit index table form q quarterly reports available copy johnson johnson 's quarterly report form q first three quarters current fiscal year without exhibits provided without charge shareowner submitting written request secretary principal executive offices company calling report available days end quarter relates part item business general johnson johnson employing approximately people worldwide engaged manufacture sale broad range products health care field operating companies conducts business virtually countries world johnson johnson 's primary interest historically currently products related human health wellbeing johnson johnson organized state new jersey johnson johnson organized principle decentralized management executive committee johnson johnson principal management group responsible allocation resources company committee oversees coordinates activities us international companies related consumer pharmaceutical medical devices diagnostics businesses international subsidiary exceptions managed citizens country located segments business geographic areas johnson johnson 's worldwide business divided three segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular graphic descriptions segments geographic areas captioned management 's discussion analysis results operations financial condition segments business consumer pharmaceutical medical devices diagnostics geographic areas pages johnson johnson 's annual report shareowners fiscal year consumer consumer segment 's principal products personal care hygienic products including nonprescription drugs adult skin hair care products baby care products oral care products first aid products sanitary protection products major brands include aveeno skin care products bandaid brand adhesive bandages benecol food products carefree panty shields clean clear teen skin care products imodium ad antidiarrheal johnson 's baby line products johnson 's ph skin hair care products lactaid lactoseintolerance products monistat remedy vaginal yeast infections adult children 's motrin ib ibuprofen products mylanta gastrointestinal products pepcid ac acid controller johnson johnson merck consumer pharmaceuticals co neutrogena skin hair care products ob tampons penaten natusan baby care products piz buin sundown sun care products reach toothbrushes roc skin care products shower shower personal care products splenda noncaloric sugar substitute stayfree sanitary protection products broad family tylenol acetaminophen products viactiv calcium supplements products marketed principally general public distributed wholesalers directly independent chain retail outlets pharmaceutical pharmaceutical segment 's principal worldwide franchises antifungal antiinfective cardiovascular dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropicurology women 's health fields products distributed directly wholesalers use health care professionals general public prescription drugs antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarin miconazole nitrate antifungal products prescription drugs antiinfective field include floxin ofloxacin levaquin levofloxacin prescription drugs cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drugs dermatology field include retina micro tretinoin dermatological cream acne prescription drugs gastrointestinal field include aciphex rabeprazole sodium sold outside us pariet proton pump inhibitor treating erosive gastroesophageal reflux disease gerd symptomatic gerd duodenal ulcers imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn 's disease patients remicade also indicated treatment rheumatoid arthritis prescription drugs hematology field include procrit epoetin alfa sold outside us eprex biotechnology derived version human hormone erythropoietin stimulates red blood cell production accounted company 's total revenues prescription drugs immunology field include orthoclone okt muromonabcd reversing rejection kidney heart liver transplants prescription drugs neurology field include reminyl galantamine topamax topiramate stugeron cinnarizine prescription drugs oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drugs pain management field include duragesic fentanyl transdermal system sold abroad durogesic transdermal patch chronic pain ultracet tramadol hydrochlorideacetaminophen shortterm management acute pain ultram tramadol hydrochloride analgesic moderate moderately severe pain prescription drugs psychotropics central nervous system field include risperdal risperidone haldol haloperidol antipsychotic drugs concerta methylphenidate attention deficithyperactivity disorder prescription drugs urology field include ditropan xl oxybutynin treatment overactive bladder prescription drugs women 's health field include orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sold us ortho tricyclen group oral contraceptives orthoprefest beta estradiolnorgestimate hormone replacement therapy sales three distributors mckesson hboc cardinal distribution amerisourcebergen corp accounted respectively total revenues sales concentrated pharmaceutical segment medical devices diagnostics medical devices diagnostics segment includes broad range products used direction health care professionals including suture mechanical wound closure products surgical equipment devices wound management infection prevention products interventional diagnostic cardiology products diagnostic equipment supplies joint replacements disposable contact lenses products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics distribution markets done directly surgical supply dealers international international business johnson johnson conducted subsidiaries located countries outside united states selling products countries throughout world products made sold international business include many described business consumer pharmaceutical medical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad investments activities countries outside united states subject higher risks comparable domestic activities investment commercial climate influenced restrictive economic policies political uncertainties raw materialsraw materials essential johnson johnson 's business generally readily available multiple sources patents trademarks johnson johnson made practice obtaining patent protection products processes possible johnson johnson owns licensed number patents relating products manufacturing processes aggregate believed material importance operation business however believed except patents related procritexprex single patent related group patents material relation johnson johnson whole johnson johnson made practice selling products trademarks obtaining protection trademarks available means johnson johnson 's trademarks protected registration united states countries products marketed johnson johnson considers trademarks aggregate material importance operation business seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research grants competition product lines johnson johnson companies compete companies large small located united states abroad competition strong lines without regard number size competing companies involved competition research involving development new products processes improvement existing products processes particularly significant results time time product process obsolescence development new improved products important johnson johnson 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition winning retention customer acceptance johnson johnson 's consumer products involve heavy expenditures advertising promotion selling research research activities important segments johnson johnson 's business major research facilities located united states also australia belgium brazil canada germany switzerland united kingdom costs johnson johnson 's worldwide research activities relating development new products improvement existing products technical support products compliance governmental regulations protection consumer amounted million fiscal years respectively costs charged directly income year incurred research sponsored johnson johnson environment past year johnson johnson subject variety federal state local environmental protection measures johnson johnson believes operations comply material respects applicable environmental laws regulations johnson johnson 's compliance requirements expected material effect upon capital expenditures earnings competitive position regulation johnson johnson 's business subject varying degrees governmental regulation countries operations conducted general trend toward regulation increasing stringency united states drug device diagnostics cosmetic industries long subject regulation various federal state local agencies primarily product safety efficacy advertising labeling exercise broad regulatory powers food drug administration fda continues result increases amounts testing documentationrequired fda clearance new drugs devices corresponding increase expense product introduction similar trends toward product process regulation also evident number major countries outside united states especially european economic community efforts continuing harmonize internal regulatory systems costs human health care continue subject study investigation regulation governmental agencies legislative bodies united states countries united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend particular medical devices even absence new government regulation managed care become potent force market place likely increased attention paid drug medical device pricing appropriate drug medical device utilization quality health care regulatory agencies whose purview johnson johnson operates administrative powers may subject johnson johnson actions product recalls seizure products civil criminal sanctions cases johnson johnson may deem advisable initiate product recalls voluntarily item properties johnson johnson worldwide subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments johnson johnson 's business approximately follows table caption square feet segment thousands c consumer pharmaceutical medical devices diagnostics worldwide total table within united states facilities used consumer segment pharmaceutical segment medical devices diagnostics segment johnson johnson 's manufacturing operations outside united states often conducted facilities serve one segment business locations manufacturing facilities major geographic areas world follows table caption number square feet geographic area facilities thousands c c united states europe western hemisphere excluding usa africa asia pacific worldwide total table addition manufacturing facilities discussed johnson johnson maintains numerous office warehouse facilities throughout world research facilities also discussed item business research johnson johnson generally seeks manufacturing facilities although principally locations abroad leased office warehouse facilities often leased johnson johnson 's properties maintained good operating conditionand repair well utilized information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements johnson johnson 's annual report shareowners fiscal year segment information additions johnson johnson 's property plant equipment contained johnson johnson 's annual report shareowners fiscal year item legal proceedings information set forth note legal proceedings notes consolidated financial statements johnson johnson 's annual report shareowners fiscal year incorporated herein reference company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company item submission matters vote security holders applicable executive officers registrant listed executive officers johnson johnson march unless otherwise indicated employee company affiliates held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors follows annual meeting shareowners executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including following executive officers directors incorporated herein reference pages johnson johnson 's proxy statement dated march table caption name age position c c robert j darretta member board directors member executive committee vice president finance russell c deyo member executive committee vice president administrationa michael j dormer member executive committee franchise group chairman medical devicesb roger fine member executive committee vice president general counselc colleen goggins member executive committee worldwide chairman consumer personal care groupd joann heffernan heisen member executive committee vice president chief information officere ralph larsen chairman board directors chief executive officer chairman executive committeef table table caption name age position c c james lenehan vice chairman board directors member executive committee worldwide chairman medical devices diagnostics group brian perkins member executive committee worldwide chairman consumer pharmaceuticals nutritionals groupg per peterson md phd member executive committee chairman research development pharmaceuticals grouph christine poon member executive committee worldwide chairman pharmaceuticals groupi william c weldon vice chairman board directors member executive committee robert n wilson senior vice chairman board directors vice chairman executive committee table mr r c deyo joined company became associate general counsel became member executive committee vice president administration b mr j dormer joined company company group chairman worldwide franchise chairman depuy codman company acquired depuy inc time acquisition chief operating officer depuy inc since mr dormer served president depuy international ltd mr dormer became member executive committee franchise group chairman medical devices february mr dormer expected named worldwide chairman medical devices diagnostics group annual meeting board directors c mr r fine joined company became member executive committee vice president administration vice president general counsel ms goggins joined company held various positions becoming president personal products company named president johnson johnson consumer products company company group chairman north america johnson johnson consumer products ms goggins became member executive committee worldwide chairman consumer personal care group june e ms j h heisen joined company became treasurer controller became member executive committee vice president chief information officer f mr larsen assumed present responsibilities chairman board directors chief executive officer mr larsen announced decision retire company july seeking reelection board directors annual meeting shareowners joined company manufacturing trainee johnson johnson products inc held numerous positions company mr larsen appointed company group chairman appointed vice chairman executive committee chairman sector operating committee later mr larsen elected board directors g mr b perkins joined company held various positions becoming president mcneil consumer products company company group chairman otc pharmaceuticals became member executive committee worldwide chairman consumer pharmaceuticals nutritionals group h dr p peterson joined company vice president drug discovery rw johnson pharmaceutical research institute named group vice president pharmaceutical research institute april president november dr peterson named chairman research development pharmaceuticals group dr peterson became member executive committee august serves president johnson johnson pharmaceutical research development llc ms poon joined company november company group chairman pharmaceuticals group ms poon became member executive committee worldwide chairman pharmaceuticals group august prior joining company served various management positions bristolmyers squibb years recently president international medicines president medical devices part ii item market registrant 's common equity related shareowner matters information called item incorporated herein referenceto material captioned management 's discussion analysis results operations financial condition common stock market prices cash dividends paid johnson johnson 's annual report shareowners fiscal year item selected financial data information called item incorporated herein reference material captioned summary operations statistical data johnson johnson 's annual report shareowners fiscal year item management 's discussion analysis financial condition results operations information called item incorporated herein reference narrative tabular graphic material included material captioned management 's discussion analysis results operations financial condition pages johnson johnson 's annual report shareowners fiscal year february board directors approved stock repurchase program authorizing company buy back billion common stock open market march shares repurchased pursuant program average per share price repurchase program time limit may suspended periods discontinued item quantitative qualitative disclosures market risk information called item incorporated herein reference material captioned management 's discussion analysis results operations financial condition financial instruments johnson johnson 's annual report shareowners fiscal year item financial statements supplementary data information called item incorporated herein reference consolidated financial statements notes thereto material captioned independent auditor 's report pages johnson johnson 's annual report shareowners fiscal year item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information called item incorporated herein reference material caption election directors nominees pages johnson johnson 's proxy statement dated march b material part hereof caption executive officers registrant c material caption section beneficial ownership reporting compliance johnson johnson 's proxy statement dated march item executive compensation information called item incorporated herein reference following sections johnson johnson 's proxy statement dated march election directors directors ' fees committees meetings pages compensation committee report executive compensation pages shareowner return performance graph executive compensation pages item security ownership certain beneficial owners management information called item incorporated herein reference material captioned election directors stock ownershipcontrol pages johnson johnson 's proxy statement dated march item certain relationships related transactions applicablepart iv item exhibits financial statement schedules reports form k following documents filed part report financial statements following consolidated financial statements notes thereto independent auditor 's report pages johnson johnson 's annual report shareowners fiscal year incorporated herein reference consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements independent auditor 's report financial statement schedules schedule ii valuation qualifying accounts schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report b reports form k report form k filed october included press release announcing company 's sales earnings fiscal quarter ended september report form k filed november included press release announcing completion company 's acquisition inverness medical technology inc 's diabetes care products business report form ka filed november amending form k filed november johnson johnson subsidiaries schedule ii valuation qualifying accounts fiscal years ended december december january dollars millions table caption additions balance charged deductions reserves balance beginning costs end period expensesb description amount period c c c c c reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed table schedule prepared give retroactive effect merger johnson johnson alza june b charges related customer rebates cash discounts reflected reductions sales customers signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date march johnson johnson registrant r larsen r larsen chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated table caption signature title date c cs r larsen chairman board directors march chief executive officer r larsen director principal executive officer r j darretta vice president finance march director principal financial r j darretta officer j cosgrove controller march j cosgrove g n burrow director march g n burrow j g cooney director march j g cooney j g cullen director march j g cullen j folkman director march j folkman jordan director march jordan g langbo director march g langbo table table caption signature title date c c jt lenehan vice chairman board directors march director jt lenehan j mayo director march j mayo lf mullin director march lf mullin h b schacht director march h b schacht f singer director march f singer j w snow director march j w snow wc weldon vice chairman board directors march director wc weldon r n wilson senior vice chairman board march directors director r n wilson table report independent accountants financial statement schedule shareowners board directors johnson johnson audits consolidated financial statements referred report dated january appearing johnson johnson annual report shareowners fiscal year ended december report consolidated financial statements incorporated reference annual report also included audit financial statement schedule listed item opinion financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york january exhibit index table caption reg sk exhibit table description item exhibit c ai restated certificate incorporation dated april incorporated herein reference exhibit registrant 's annual report year ended december aii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit registrant 's annual report year ended january aiii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit aiii registrant 's annual report year ended december aiv certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july b bylaws company amended effective june incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july upon request securities exchange commission registrant furnish copy instruments defining rights holders long term debt registrant stock option plan nonemployee directors incorporated herein reference exhibit registrant 's annual report year ended december b stock option plan incorporated herein reference exhibit b registrant 's annual report year ended december c stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended january stock option plan amended incorporated herein reference exhibit c registrant 's annual report year ended december e stock compensation plan incorporated herein reference exhibit e registrant 's annual report year ended december f executive incentive plan amended incorporated hereinby reference exhibit f registrant 's annual report year ended december g domestic deferred compensation certificate extra compensation plan amended filed document h deferred fee plan directors amended incorporated herein reference exhibit h registrant 's annual report year ended december executive income deferral plan amended incorporated herein reference exhibit registrant 's annual report year ended january j excess savings plan incorporated herein reference exhibit j registrant 's annual report year ended december k supplemental retirement plan incorporated herein reference exhibit h registrant 's annual report year ended january l executive life insurance plan incorporated herein reference exhibit registrant 's annual report year ended january table table caption reg sk exhibit table description item exhibit c stock option gain deferral plan incorporated herein reference exhibit registrant 's annual report year ended january n estate preservation plan incorporated herein reference exhibit n registrant 's annual report year ended january statement computation ratio earnings fixed charges filed document pages company 's annual report shareowners fiscal year portions annual report incorporated reference report deemed filed filed document subsidiaries filed document consent independent accountants filed document annual reports form k johnson johnson savings plans filed june b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document table management contracts compensatory plans arrangements required filed exhibits form pursuant item c report copy exhibits listed provided without charge shareowner submitting written request specifying desired exhibits secretary principal executive offices company text document document typeexg sequence filenameyexgtxt descriptiondomestic deferred compensation plan amended text exhibit g johnson johnson certificate extra compensation planwitnesseth whereas johnson johnson company wishes reward employees well employees subsidiaries employee faithful service past particularly encourage employees future work permitting employees share growth success company 's enterprises issuing shares certificates extra compensation cec shares end receive extra compensation sums based upon measured amount cash dividends time time declared upon equal number shares common stock company common stock b formula value cec shares established pursuant article ninth plan formula value time termination employment death employment therefore consideration premises promises herein contained long employee shall remain employee agreed first number cec shares designated upon employee 's extra compensation shall based aggregate number cec shares awarded employee accordance plan evidenced written records company second employee remains employee company shall pay employee date paid cash dividend company 's common stock sum equivalent cash dividend multiplied total number cec shares designated employee third event employee 's death employee company shall pay employee 's beneficiary last recorded employee 's signature records company sum money shall determined percentage formula value cec shares percentage shall based upon period elapsing date cec share awarded death follows event death within eighteen months date award event death eighteen months within fortytwo months date award event death fortytwo months date award event termination employee 's employment retirement physical mental disability otherwise except reason death company shall pay employee sum money shall determined percentage formula value cec shares purposes plan employee placed longterm disability considered employee percentage shall based upon period elapsing date cec share awarded termination employment follows event termination within twelve months date award event termination twelve months within twentyfour months date award event termination twentyfour months within thirtysix months date award event termination thirtysix months within fortyeight months date award event termination fortyeight months within sixty months date award event termination sixty months date award company shall pay sum money due article third single lump sum unless employee duly elected pursuant provisions article seventh defer receipt sum upon hisher retirement fourth election employee made provided payment sum due employee upon hisher retirement may deferred paid either single lump sum installments lump sum payment may deferred ten taxable years following employee 's retirementdate installment payments elected first installment payment may made immediately upon retirement deferred ten taxable years installment payments made annually manner described approximately equal installment amounts ie value cec payout balance plus accrued interest divided number remaining installments minimum number annual installments two maximum number fifteen employee may elect defer value hisher total cec holdings retirement percentage increment less following rules shall apply respect payments immediate lump sum payment employee receive full value hisher cec holdings calendar month hisher retirement effective date employees retiring prior determination prior years cec value receive estimated value remainder paid shortly final value determined b deferred lump sum payment employee receive full value hisher cec holdings plus accrued interest january year heshe elects receive payment c immediate commencement installments employee receive first installment calendar month hisher retirement effective date subsequent installments plus accrued interest paid january year deferred commencement installments employee receive first subsequent installments plus accrued interest january year fifth respect payments deferred andor paid installments interest shall paid company effective date retirement date payment interest rate deferred andor installment payments employee shall fixed date retirement shall rate rounded decimal place offered reported wall street journal effective retirement date united states treasury instrument period comparable length period deferral andor installment payments interest shall compounded semiannually last calendar day june december year one instrument quoted average rates shall utilized way example election made receive installments eight years comparable eight year us treasury rate shall utilized election made defer commencement installments two years installments paid ten years comparable twelve year us treasury rate shall utilized established interest rate shall remain fixed period deferral sixth event death employee whether prior termination hisher employment company make payment full balance plus accrued interest soon administratively practical single lump sum payment designated beneficiary event deferral installment election made total amount cec holdings paid accordance provisions paragraph article fourth lump sum payment soon practical following employee 's retirement effective date seventh election employee defer payment elect installments part hisher cec holdings beyond hisher effective retirement date must made minimum twelve months prior date retirement date election may revised revoked twelve months prior retirement date twelve month period prior retirement date election irrevocable thus may revoked otherwise revised company may disallow employee 's desire defer payments andor elect installments determines participation would jeopardize plan 's compliance applicable law plan 's status top hat plan erisa notwithstanding exception made employees retirement effective date january june employees deferral andor installment election must made minimum three months calendar year prior retirement date example employee retires january must make deferral andor installment election later september retirement date may election must made later december respect retirement occurring july december election must made prior december election defer andor receive installment payments may revised revoked prior last permissible date making election time election may revoked otherwise revised election defer payment andor paid installments effective filed administrator referred article fifteenth form utilized purpose election made required deadline shall disregarded election defer andor paid installments made consultation employee 's tax andor financial advisor eighth number cec shares designated upon based measured extra compensation employee shall increased proportionately time time extent stock split dividend common stock declared paid upon issued outstanding common stock company likewise number cec shares shall reduced proportionately time time extent number cec shares issued outstanding common stock company reduced reorganization reduction capital otherwise ninth purposes article third agreement formula value cec shares shall determined company 's board directors shall except event mentioned determine formula value sum onehalf asset value per share common stock plus onehalf earningpower value per share common stock calculated follows sum onehalf consolidated net asset value per share common stock assets per share less liabilities including reserves surplus reserve per share assets liabilities appear books company subsidiaries fiscal year end immediately preceding date valuation plus onehalf consolidated earningpower value per share common stock determined average annual net earnings per share common stock taxes net earnings appear books company subsidiaries five fiscal years preceding date valuation capitalized return capital invested eight percent ie multiple twelve onehalf times average earnings per share purpose foregoing calculation books company subsidiaries shall conclusive method consolidation shall adopted company preparing last previous annual report stockholders including appropriate provision taxes foreign domestic might incurred remitting income subsidiaries company decisions company 's treasurer times time time procedures adopted maintaining books company subsidiaries preparation balance sheets income statements method adjustments made consolidation matters accounting practice procedures shall conclusive event shall opinion board directors company calculation made provided result true value date article third determination necessary board may shall obligated vary formula extent modifying multiple average earnings per share shall multiplied board directors shall may fifteenth year determine announce formula value company 's common stock immediately preceding fiscal year end purposes plan tenth dividends share values used herein measures extra compensation paid hereunder nothing herein contained shall construed agreement transfer employee hisher beneficiary shall either acquire virtue hisher awarded cec shares right title interest whatsoever company 's common stock eleventh right benefit cec shares awarded plan assignable company fund obligations created employee participation cec plan rather company makes unsecured promise pay obligations general corporate assets applies obligations active retired participants commencing awards made year end certificates representing cec shares longer issued instead number cec shares awarded shall recorded books company twelfth regular parttime employees working hours week shall considered employees plan change parttime status ofless hours week shall considered termination provided however event employee age employee shall purposes plan deemed retired nothing contained plan shall construed alter present employment indefinite term terminable either employee company without prior advance notice thirteenth employee leaves company one subsidiaries request company work joint venture operation company one subsidiaries minority partnership interest may sole discretion management compensation committee considered employee solely purposes plan period three years following departure company arrangement may extended two additional years management compensation committee sole discretion determines best interest company person ceases employment joint venture operation without concomitant return employment company one subsidiaries person shall immediately considered terminated cease considered employee purposes plan fourteenth employee may designate one beneficiaries receive value hisher payout upon death beneficiary predecease employee beneficiary named amount designated beneficiary employee 's payout balance case may distributed employee 's estate beneficiary designations may made revised time submitting beneficiary designation form company beneficiary beneficiaries indicated form shall supersede prior designation including designations appearing certificates representing cec shares fifteenth first quarter calendar year statements sent active employees participating cec plan well retirees deferred cec holdings report active employees provide value cec holdings based prior years ' final cec value statement also include previously made deferral elections beneficiary designations report retirees provide deferred cec payout balance plus interest well deferred andor installment election beneficiary designations sixteenth cec plan administered extra compensation services department corporate headquarters company questions regard administration cec plan addressed text document document typeex sequence filenameyextxt descriptionstatement computation ratio earnings text exhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions table caption fiscal year ended december december january january december c c c c c determination earnings earnings provision taxes income fixed charges total earnings defined fixed charges rents interests fixed charges capitalized interest total fixed charges ratio earnings fixed charges table ratio earnings fixed charges represents historical ratio johnson johnson calculated total enterprise basis ratio computed dividing sum earnings provision taxes fixed charges excluding capitalized interest fixed charges fixed charges represent interest including capitalized interest amortization debt discount expense interest factor rentals consisting appropriate interest factor operating leases earnings year ended january include charges related restructuring million inprocess research development charges million excluding effect charges ratio earnings fixed charges would text document document typeex sequence filenameyextxt descriptionpages company 's annual report text management 's discussion analysis results operations financial condition overview record sales billion exceeded sales billion marked th year consecutive positive sales growth growth led strong performances pharmaceutical medical devices diagnostics segments company completed merger alza corporation researchbased pharmaceutical company innovative drug delivery technologies completed acquisition inverness medical technology supplier lifescan 's electromechanical products investments part company 's continuing commitment build strong science technologybased business balance sheet remains strong cash generated worldwide operations record billion cash dividends per share paid shareowners increased represented th consecutive year cash dividend increases company continues one companies triple credit rating company 's objective achieve superior levels capital efficient profitable growth accomplish company 's management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth segments development innovative products services billion sales invested research development recognizing importance ongoing development new differentiated products services company 's system management operates decentralized basis operating companies located countries company views management philosophy asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability react quickly local market changes challenges businesses managed long term order sustain leadership positions achieve growth provides enduring source value shareowners unifying management team company 's dedicated employees achieving objectives johnson johnson credo credo provides common set values serves constant reminder company 's responsibilities customers employees communities shareowners thecompany believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry description business company subsidiaries employees worldwide engaged manufacture sale broad range products health care field company conducts business virtually countries world company 's primary interest historically currently products related human health wellbeing company organized principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities domestic international companies span consumer pharmaceutical medical devices diagnostics businesses international subsidiary exceptions managed citizens country located product lines company competes companies large small located united states america abroad competition strong lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important company 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition winning retention customer acceptance company 's consumer products involves heavy expenditures advertising promotion selling sales customers bar graph sales customers millions dollars table caption c c c c c c c c c c domestic international table sales earnings worldwide sales increased billion compared increases sales three distributors mckesson hboc cardinal distribution amerisourcebergen corp accounted respectively total revenues excluding impact foreign currencies worldwide sales increased net earnings bar graph net earnings millions dollars table caption c c c c c c c c c c c earnings table results excluding restructuring inprocess rd charges worldwide net earnings billion reflecting increase worldwide net earnings per share equaled per share increase net earnings per share excluding impact special charges worldwide net earnings billion net earnings per share representing increase respectively aftertax special charges taken include million related alza merger completed june million inprocess research development iprd costs associated acquisitions inverness medical technology teramed inc completed fourth quarter worldwide net earnings billion reflecting increase worldwide net earnings per share equaled per share increase net earnings per share excluding impact special charges worldwide net earnings billion net earnings per share representing increase respectively special charges taken included iprd costs associated acquisitions atrionix inc crescendo million net favorable adjustment million costs associated global manufacturing restructuring charge income expense included gains related sale certain equity securities worldwide net earnings billion reflecting increase worldwide net earnings per share equaled per share increase net earnings per share excluding impact special charges worldwide net earnings billion net earnings per share representing increase respectively special charges included costs associated centocor sequus mergers reconfiguration worldwide manufacturing network iprd charges average diluted shares common stock outstanding billion sales domestic companies billion billion billion represents increase sales international companies billion billion billion represents increase excluding impact foreign currency fluctuations past three years international company sales increased geographic areas throughout world posted operational gains excluding effect exchange rate fluctuations us dollar foreign currencies sales increased europe western hemisphere excluding us asiapacific africa regions company achieved annual compound growth rate worldwide sales year period since domestic sales growing rate international sales growing rate worldwide net earnings achieved year annual growth rate earnings per share grew rate last five years annual compound growth rate sales annual compound growth rate net earnings annual compound growth rate earnings per share excluding impact foreign currency fluctuations annual compound growth rate sales year period year period respectively distribution sales revenues distribution sales revenues table caption c c c employment costs costs materials services depreciation amortization property intangibles taxes payroll earnings reinvested business cash dividends paid special chargesiprd table cost expenses research activities represent significant part company 's business expenditures relate development new products improvement existing products technical support products compliance governmental regulations protection consumer worldwide costs research activities excluding special charges iprd follows table caption millions dollars c c c research expense percent increase prior year percent sales table research expense percent sales pharmaceutical segment averaging two segments respectively research expense bar graph table caption research expense millions dollars c c c c c c c c c c expenses table advertising expenses comprised television radio print media well internet advertising billion billion billion company believes operations comply material respects applicable environmental laws regulations company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research grants worldwide effective income tax rate refer note additional information segments business financial information company 's three worldwide business segments summarized see note additional information segments business sales segment business bar graphtable caption sales segment business millions dollars c c c consumer pharmaceutical medical devices diagnostics total amount table table caption sales increase millions dollars amount percent c c c c consumer pharmaceutical med devices diag worldwide total table operating profit segment business bar graph table caption operating profit segment business millions dollars c c c consumer pharmaceutical med devices diag worldwide total table results include special charges related alza merger inprocess research development excluding charges operating profit percentage sales pharmaceutical segment medical devices diagnostics segment results include special charges related inprocess research development gain related restructuring excluding charges operating profit percentage sales consumer segment pharmaceutical segment medical devices diagnostics segment results include special charges related centocor sequus mergers excluding charges operating profit percentage sales pharmaceutical segment table caption operating profit percent sales millions dollars c c c c consumer pharmaceutical med devices diag segments total expenses allocated segments earnings taxes income table results include special charges related alza merger inprocess research development excluding charges operating profit percentage sales pharmaceutical segment medical devices diagnostics segment results include special charges related inprocess research development gain related restructuring excluding charges operating profit percentage sales consumer segment pharmaceutical segment medical devices diagnostics segment consumer consumer segment 's principal products personal care hygienic products including nonprescription drugs adult skin hair care products baby care products oral care products first aid products sanitary protection products major brands include neutrogena skin hair care products aveeno skin care products bandaid brand adhesive bandages benecol food products carefree panty shields clean clear teen skin care products imodium ad antidiarrheal johnson 's baby line products johnson 's ph skin hair care products monistat remedy vaginal yeast infections adult children 's motrin ib analgesic products mylanta gastrointestinal products pepcid ac acid controller johnson johnson merck consumer pharmaceuticals co ob tampons penaten natusan baby care products piz buin sundown sun care products reach toothbrushes roc skin care products shower shower personal care products splenda noncaloric sugar substitute stayfree sanitary protection products broad family tylenol acetaminophen products products marketed principally general public distributed wholesalers directly independent chain retail outlets consumer segment sales billion increase domestic sales increased international sales gains local currency offset negative currency impact consumer sales experienced strong growth mcneil nutritionals ' splenda sweetener products recently acquired viactiv brand calcium supplement solid growth also achieved skin care franchise includes neutrogena roc aveeno clean clear product lines fourth quarter company introduced neutrogena men 's line consisting eight premium skin care products provide dermatologist tested clinically proven solutions men 's skin care problems consumer segment sales billion increase domestic sales increased international sales gains local currency offset negative currency impact consumer sales led continued strength skin care franchise includes neutrogena roc aveeno clean clear product lines well strong performances johnson 's line baby skin care products company acquired st joseph aspirin business acquisition first entry cardioprotective aspirin market mcneil consumer specialty pharmaceuticals world leader overthecounter analgesics consumer segment sales billion increase domestic sales increased international sales declined international sales gains local currency offset negative currency impact company launched various products included benecol dietary ingredient stanol ester aids reduction cholesterol also completed acquisition aveeno brand products pharmaceutical pharmaceutical segment 's principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology fields products distributed directly wholesalers use health care professionals general public prescription drugs antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarin miconazole nitrate antifungal products prescription drugs antiinfective field include floxin ofloxacin levaquin levofloxacinprescription drugs cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drugs contraceptive field include orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sold us ortho tricyclen group oral contraceptives prescription drugs dermatology field include retina micro tretinoin dermatological cream acne prescription drugs gastrointestinal field include aciphex rabeprazole sodium sold outside us pariet proton pump inhibitor treating erosive gastroesophageal reflux disease gerd duodenal ulcers imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn 's disease patients remicade also indicated treatment rheumatoid arthritis prescription drugs hematology field include eprex epoetin alfa sold us procrit biotechnology derived version human hormone erythropoietin stimulates red blood cell production prescription drugs immunology field include orthoclone okt muromonabcd reversing rejection kidney heart liver transplants prescription drugs neurology field include topamax topiramate reminyl galantamine stugeron cinnarizine prescription drugs oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drugs psychotropics central nervous system field include antipsychotic drugs risperdal risperidone haldol haloperidol concerta methylphenidate attention deficit hyperactivity disorder prescription drugs pain management field include duragesic fentanyl transdermal system sold abroad durogesic transdermal patch chronic pain ultram tramadol hydrochloride analgesic moderate moderately severe pain prescription drugs urology field include ditropan xl oxybutynin treatment overactive bladder johnson johnson markets prescription drugs around world sales generated outside united states america thirtythree drugs sold company sales excess million excess million pharmaceutical segment sales billion increase including growth domestic sales operationally international sales increased partially offset negative currency impact worldwide sales gains local currency partially offset negative currency impact sales growth reflects strong performance procriteprex risperdal duragesic concerta remicade ultram topamax aciphexpariet sales procriteprex accounted total company revenues fourth quarter company received us food drug administration fda approval ortho evra first birth control patch ortho evra thin beige patch delivers continuous levels hormones norelgestromin ethinyl estradiol progestin estrogen respectively skin bloodstream patch worn one week time replaced day week three consecutive weeks fourth week patchfree company also filed several new drug applications fda december include levaquin treatment nosocomial pneumonia orally disintegrating formulation risperdal synthetic oral solution reminyl alzheimer 's disease pharmaceutical segment sales billion increase including growth domestic sales operationally international sales increased offset negative currency impact worldwide sales gains local currency partially offset negative currency impact sales growth reflects strong performance procriteprex risperdal duragesic levaquin remicade ultram topamax aciphexpariet oral contraceptive line products sales growth partially offset restricted access limited indications propulsidprepulsid number markets around world pharmaceutical segment sales billion increase including growth domestic sales international sales increased sales gains local currency offset negative currency impact worldwide growth reflected strong performance procrit risperdal duragesic levaquin oral contraceptive line products significant research activities continued pharmaceutical segment increasing billion sales representsan increase compound annual growth rate approximately fiveyear period since johnson johnson pharmaceutical research development llc formerly known janssen research foundation rw johnson pharmaceutical research institute worldwide pharmaceutical research organization additional research conducted centocor alza collaboration james black foundation london england medical devices diagnostics medical devices diagnostics segment includes broad range products used direction health care professionals include suture mechanical wound closure products surgical equipment devices wound management infection prevention products interventional diagnostic cardiology products diagnostic equipment supplies joint replacements disposable contact lenses products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics acquisitions medical devices diagnostics segment recent years integral part ongoing process transform segment principally medical supply business one serving range higher technology medical specialties worldwide sales billion medical devices diagnostics segment represented increase domestic sales international sales increased sales gains local currency offset negative currency impact worldwide sales gains local currency reduced due strength us dollar strong sales growth cordis ' circulatory disease management products depuy 's orthopaedic joint reconstruction spinal products ethicon 's wound closure surgical sports medicine women 's health products ethicon endosurgery 's minimally invasive surgical vascular access products lifescan 's blood glucose monitoring products primary contributors medical devices diagnostics segment growth fourth quarter cordis announced fda approval bx velocity coronary stent hepacoat raptorrail stent delivery system rapid exchange stent coated heparin bloodthinning agent used reduce risk clot formation addition cordis completed acquisition teramed inc privately held company developing proprietary catheterbased system treatment abdominal aortic aneurysms november company completed acquisition inverness medical technology manufacturer developer advanced blood glucose monitoring products inverness wholly owned subsidiary johnson johnson together johnson johnson 's lifescan business unit forms leading blood glucose monitoring franchiseinverness medical technology acquired order provide technology development future products additionally vistakon introduced acuvue colours brand contact lenses provides exceptional comfort handling soft frequent replacement color contact lens acuvue colours twoweek daily wear lens available without vision correction seven naturallooking colors unique colourswrappedincomfort design eliminates color touching eye offering natural color depth worldwide sales billion medical devices diagnostics segment represented increase domestic sales international sales increased sales gains local currency offset negative currency impact worldwide sales gains local currency reduced due strength us dollar strong sales growth cordis ' coronary endovascular stents depuy 's spinal products ethicon 's mitek suture anchors gynecare 's women 's health products ethicon endosurgery 's mammotome breast biopsy system ultracision harmonic scalpel vistakon 's disposable contact lens products primary contributors medical devices diagnostics segment growth worldwide sales billion medical devices diagnostics segment represented increase domestic sales increased international sales gains local currency partially offset strength us dollar fourth quarter cordis launched new bx velocity coronary stent europe well received medical community ethicon 's new products included pronova poly hexafluoropropylenevdf suture synthetic nonabsorbable monofilament cardiovascular vascular surgery surgifoam absorbable gelatin sponge usp proven surgery years europe givenethicon full line hemostasis products ethicon also received approval gynecare 's thermachoice ii uterine balloon therapy system latexfree next generation ablation technology system used excessive uterine bleeding geographic areas company 's sales major geographic area presented table caption sales increase millions dollars amount percent c c c c united states europe western hemisphere excluding us asiapacific africa worldwide total table international sales negatively impacted translation local currency operating results us dollars regions average exchange rates dollar declined year since see note additional information geographic areas sales geographic area business bar graph sales geographic area business millions dollars table caption c c c united states europe western hemisphere excluding us asiapacific africa total sales dollars table liquidity capital resources cash generated operations selected borrowings provides major source funds growth business including working capital additions property plant equipment acquisitions cash current marketable securities totaled billion end compared billion end year ended december change timing salary increases bonuses employees december february change enacted results finalized order align compensation performance result change increase approximately million accrued salaries wages commissions balance sheet december results corresponding increase cash flows operating activities total unused credit available company approximates billion including billion credit commitments various banks worldwide expire october company 's shelf registration filed securities exchange commission enables company issue billion unsecured debt securities warrants purchase debt securities medium term note mtn program mtns issued december company billion remaining shelf registration company continues one companies triple credit ratingtotal borrowings end billion billion respectively net cash cash current marketable securities net debt billion net cash cash current marketable securities net debt billion total debt represented total capital shareowners ' equity total debt total capital shareowners ' equity per share end compared yearend increase period ended december material cash commitments summary borrowings found note february company announced stock repurchase program billion time limit program financial instruments company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value existing foreign currency assets liabilities hedge future foreign currency product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value company 's forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value company 's forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future earnings cash flows company enters currency swap contracts manage company 's exposure changes currency exchange rates hedge foreign currency denominated assets liabilities impact change interest rates company 's interest rate sensitive financial instruments would immaterial company enter financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions company significant exposure one counterparty management believes risk loss remote changing prices inflation johnson johnson aware products used setting decade policymakers consumers businesses expressed concern rising cost health care response concerns johnson johnson longstanding policy pricing products responsibly period united states weighted average compound annual growth rate johnson johnson price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi period inflation rates even though moderate many parts world continue effect worldwide economies consequently way companies operate face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases key accounting policies new accounting pronouncements previously described company engaged manufacture sale products healthcare field due nature business unlikely accounting policies open interpretation could material effect company 's results operations certain key accounting policies may affect results company timing revenue recognition fact research development expenses expensed incurred note consolidated financial statements describes company 's significant accounting policies emerging issues task force eitf reached consensus accounting certain sales incentives eitf addresses recognition measurement statement earnings classification certain sales incentives additionally eitf issue vendor income statement characterization consideration paid reseller vendor 's products eitf addresses classification statement earnings consideration vendor entity purchases vendor 's products resale pronouncements effective beginning first quarter impact pronouncements company 's financial statements result corresponding reduction sales expenses estimated million million million respectively eitf million million million respectively eitf june financial accounting standards board fasb issued pronouncement sfas business combinations sfas requires purchase method accounting must used business combinations initiated june eliminates use poolingofinterests method accounting sfas also clarifies criteria recognition intangible assets separately goodwill sfas goodwill intangible assets sfas effective january also issued fasb june sfas eliminates amortization goodwill indefinitelived intangible assets initiates annual review impairment identifiable intangible assets determinable useful life continue amortized amortization goodwill intangible assets acquired prior june eliminated upon adoption sfas rules established sfas applied immediately goodwill intangible assets acquired june see notes additional information june fasb issued sfas accounting asset retirement obligations addresses accounting reporting entity 's legal obligations associated retirement longlived assets due acquisition development normal operation asset pronouncement effective fiscal year beginning june october fasb issued sfas accounting impairment disposal longlived assets sfas effective first quarter sfas addresses financial accounting reporting impairment disposal longlived assets sfas supersedes sfas accounting impairment longlived assets longlived assets disposed accounting reporting provisions accounting principles board opinion reporting results operationsreporting effects disposal segment business extraordinary unusual infrequently occurring events transactions segments business disposed previously defined opinion implementations sfas sfas expected material effect company 's results operations cash flows financial position common stock market prices company 's common stock listed new york stock exchange symbol jnj composite market price ranges adjusted stock split effective may johnson johnson common stock table caption high low high low c c c c first quarter second quarter third quarter fourth quarter yearend close table cash dividends paid company increased dividends th consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows table caption c c cfirst quarter second quarter third quarter fourth quarter total table january board directors declared regular cash dividend per share paid march shareowners record february company expects continue practice paying regular cash dividends cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company assumes obligation update forwardlooking statements result new information future events developments company 's report year ended december filed march contain exhibit discussion various factors could cause actual results differ expectations prior filing investors reference company 's report fiscal year ended december company notes factors permitted private securities litigation reform act consolidated balance sheets johnson johnson subsidiaries table caption december december dollars millions note c c assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes deferred taxes income note assets total assets liabilities shareowners ' equity current liabilitiesloans notes payable note accounts payable accrued liabilities accrued salaries wages commissions taxes income total current liabilities longterm debt note deferred tax liability note employee related obligations note liabilities shareowners ' equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares note receivable employee stock ownership plan note accumulated comprehensive income note retained earnings less common stock held treasury cost note total shareowners ' equity total liabilities shareowners ' equity table see notes consolidated financial statements consolidated statements earnings johnson johnson subsidiaries table caption dollars millions except per share figures note c c c sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes table see notes consolidated financial statements consolidated statements equity johnson johnson subsidiaries table caption note receivable accumulated common employee stock treasury comprehensive retained stock ownership comprehensive issued stock dollars millions note total income earnings plan esop income amount amount c c c c c c c balance january net earnings cash dividends paid employee compensation stock option plans repurchase common stock business combinations comprehensive income net tax currency translation adjustment unrealized gains losses securities reclassification adjustment total comprehensive income note receivable esop balance january net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adjustment unrealized gains losses securities pension liability adjustment reclassification adjustment total comprehensive income note receivable esop balance december net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adjustment unrealized gains losses securities pension liability adjustment gainslosses derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance december table see notes consolidated financial statements consolidated statements cash flows johnson johnson subsidiaries table caption dollars millions note c c c cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles purchased inprocess research development increase deferred taxes accounts receivable reserves changes assets liabilities net effects acquisition businesses increase accounts receivable increase decrease inventories increase accounts payable accrued liabilities increase decrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisition businesses net cash acquired note purchases investments sales investments net cash used investing activities cash flows financing activities dividends shareowners repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions businesses fair value assets acquired fair value liabilities assumed treasury stock issued fair value net cash paid acquisitions table see notes consolidated financial statements notes consolidated financial statements summary significant accounting principles basis presentation consolidated financial statements johnson johnson prepared give retroactive effect merger alza corporation alza june principles consolidation financial statements include accounts johnson johnson subsidiaries intercompany accounts transactions eliminated cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value longterm debt securities company ability intent hold maturity carried amortized cost also approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets table c building building equipment years land leasehold improvements years machinery equipment years table revenue recognition company recognizes revenue product sales goods shipped delivered title passes customersales incentives trade promotional allowances company currently recognizes expense related coupons certain sales incentives trade promotions upon issuance classifies expenses selling marketing administrative expense company adopt eitf issues effective beginning first quarter impact company reclassification expense reduction sales million million million eitf million million million eitf shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling immaterial periods presented inventories inventories stated lower cost market determined firstin firstout method intangible assets acquisitions completed june excess cost fair value net assets purchased businesses recorded goodwill amortized straightline basis periods years less cost acquired intangibles amortized straightline basis estimated useful lives company continually evaluates carrying value goodwill intangible assets impairments would recognized expected future operating cash flows derived intangible assets less carrying value company adopted sfas business combinations sfas goodwill intangible assets business combinations consummated july accounted accordance new pronouncements goodwill relating acquisitions completed subsequent june amortized subject impairment testing addition effective january company longer required amortize goodwill certain intangible assets relating acquisitions completed prior july financial instruments effective january company adopted sfas accounting derivative instruments hedging activities amended sfas accounting certain derivative instruments certain hedging activities amendment fasb statement collectively referred sfas sfas requires derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction depending type hedge transaction company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future product purchases denominated foreign currency company also uses currency swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses forward exchange contracts offset exposure certain foreign currency assets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities designation cash flow hedge made later date entering derivative contract january inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassed earnings account hedged transaction fair value forward exchange contract represents present value change forward exchange rates times notional amount derivative fair value currency swap contract determined discounting present future cash flows currencies exchanged interest rates prevailing market periods currencyexchanges due expressing result us dollars current spot foreign currency exchange rate inception ongoing basis company assesses whether derivative expected highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposure 's impact company 's financial performance protect company 's cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions advertising costs associated advertising expensed year incurred advertising expenses worldwide comprised television radio print media well internet advertising billion billion billion income taxes company intends continue reinvest undistributed international earnings expand international operations therefore tax provided cover repatriation undistributed earnings december december cumulative amount undistributed international earnings approximately billion billion respectively net earnings per share basic earnings per share computed dividing net income available common shareowners weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities contracts issue common stock exercised converted common stock risks uncertainties preparation consolidated financial statements conformity accounting principles generally accepted united states requires management make estimates assumptions affect amounts reported actual results may may differ estimates annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years case fiscal year consists weeks reclassification certain prior year amounts reclassified conform current year presentation stock split april board directors declared stock split shareowners record close business may issued one additional share johnson johnson common stock june share held record date shares per share data periods presented financial statements adjusted reflect stock split inventories end inventories comprised table caption dollars millions c craw materials supplies goods process finished goods table property plant equipment end property plant equipment cost accumulated depreciation table caption dollars millions c c land land improvements buildings building equipment machinery equipment construction progress less accumulated depreciation table company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively upon retirement disposal fixed assets cost related amount accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds adjusted earnings rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases amounted approximately million million million approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december table caption dollars millions total c c c c c c c table commitments capital leases significant employee related obligations end employee related obligations table caption dollars millions c c post retirement benefits post employment benefits pension liabilities deferred compensation employee related obligations table borrowings components longterm debt follows table caption eff eff dollars millions rate rate c c c c zero coupon convertible subordinated debentures due zero coupon convertible subordinated debentures due convertible subordinated debentures due debentures due notes due debentures due eurodollar due notes due eurodollar notes due notes due deutsche mark notes due notes due industrial revenue bonds principally international less current portion table weighted average effective rate represents deutsche mark notes due issued japanese subsidiary converted fixed rate yen note via currency swap represents us dollar notes due issued japanese subsidiary converted fixed rate yen note via currency swap company access substantial sources funds numerous banks worldwide total unused credit available company approximates billion including billion credit commitments various banks worldwide expire october interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material company 's shelf registration filed securities exchange commission enables company issue billion unsecured debt securities warrants purchase debt securities medium term note mtn program mtn 's issued december company billion remaining shelf registration long term debt includes convertible subordinated debentures issued centocor alza prior respective mergers johnson johnson respect convertible subordinated debentures originally issued centocor company exercised option redeem debentures set february redemption date price equal principal amount plus accrued interest debentures converted holders approximately million shares johnson johnson stock conversion price per share july alza completed private offering zero coupon convertible subordinated debentures issued price per principal amount maturity december outstanding debentures total principal amount maturity billion yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures holders entitled convert debentures approximately million shares johnson johnson stock price per share approximately shares issued december due voluntary conversions note holders option holder debentures may repurchased company july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either johnson johnson common stock cash combination stock cash event repurchase debentures company option may also redeem debentures july issue price plus accreted original issue discount december december fair value based quoted market value debentures million million respectively alza issued zero coupon convertible subordinated debentures price per principal amount maturity december outstanding debentures total principal amount maturity million yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures note holders entitled convert debentures approximately million shares johnson johnson stock price per share approximately million shares johnson johnson stock issued december due voluntary conversions note holders option holder debentures may purchased company july july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either common stock cash event conversion purchase debentures company option may also redeem debentures cash july redemption price equal issue price plus accreted original issue discount december december fair value based quoted market value debentures million million respectively shortterm borrowings current portion longterm debt amounted million end borrowings comprised million notes million local borrowings principally international subsidiaries aggregate maturities longterm obligations commencing table caption dollars millions c c c c c c table intangible assets end gross net amounts intangible assets table caption dollars millions c c goodwill gross less accumulated amortization goodwill net patents trademarks gross less accumulated amortization patents trademarks net intangibles gross less accumulated amortization intangibles net total intangible assets gross less accumulated amortization total intangible assets net table weighted average amortization periods goodwill patents trademarks intangibles years years years respectively intangible assets include billion related acquisitions completed june accounted new provision sfas sfas effect implementation new provisions intangibles recorded prior june reduction amortization expense approximately million prospectively refer note additional information income taxes provision taxes income consists table caption dollars millions c c c currently payable us taxes international taxes deferred us taxes international taxes table comparison income tax expense federal statutory rate company 's effective tax rate follows table caption dollars millions c c c us international earnings taxes income statutory taxes tax rates statutory puerto rico ireland operations research tax credits domestic state local international subsidiaries excluding ireland iprd effective tax rate tableduring company subsidiaries operating puerto rico tax incentive grant expiring addition company subsidiaries manufacturing ireland incentive tax rate effective year deferred income taxes recognized tax consequences temporary differences applying enacted statutory tax rates applicable future years differences financial reporting tax basis existing assets liabilities temporary differences carryforwards follows table caption deferred tax dollars millions asset liability c c employee related obligations depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes miscellaneous international capitalized intangible miscellaneous us total deferred income taxes table difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet international currency translation translation nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies reflected operating results analysis changes foreign currency translation adjustments included note net currency transaction translation gains losses included expense aftertax losses million million million respectively common stock stock option plans stock compensation agreements december company stockbased compensation plans stock option plan company may grant options employees issued shares company 's common stock plus number shares available previous year issued well shares issued plan expired terminated without exercised shares outstanding contracts company 's employee stock option plans nonemployee director 's plan mitek cordis biosense gynecare centocor innovasive devices alza inverness stock option plans stock options expire years date granted vest service periods range one six years options granted current market price date grant shares available stock option plan future grants based issued shares year million shares could granted year years addition available shares described shares available future grants plan million theend summary status company 's stock option plans december december january changes years ending dates presented table caption weighted options average shares thousands outstanding exercise price c c balance january options granted options exercised options canceledforfeited balance january options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance december table includes options issued replace inverness options outstanding granted prior acquisition year ended december change timing granting stock compensation options employees december february change enacted results finalized order align compensation performance company applies provision financial accounting standards accounting stockbased compensation calls companies measure employee stock compensation expense based fair value method accounting however allowed statement company elected continued use accounting principle board apb opinion accounting stock issued employees pro forma disclosure net income earnings per share determined fair value method applied measuring compensation cost fair value method applied net income would reduced million per share million per share million per share calculations take account options issued since january average fair value options granted fair value estimated using blackscholes option pricing model based weighted average assumptions table caption c c c riskfree rate volatility expected life yrs yrs yrs dividend yield table following table summarizes stock options outstanding exercisable december table caption shares thousands outstanding exercisable average average exercise average exercise exercise price range options lifea price options price c c c c c table average contractual life remaining years accumulated comprehensive income components comprehensive incomeloss consist following table caption total unrealized gains accumulated foreign gains pension losses currency losses liability derivatives comprehensive dollars millions translation securities adjustments hedges incomeloss c c c c c jan changes jan changes dec changes transition adjustment net change due hedging transactions net amount reclassed net earnings net changes dec table total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income included reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income included reclassification adjustment losses million associated tax benefit million tax effect unrealized gainslosses equity securities expense million million million tax effect gainslosses derivatives hedges expense million see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments nonus subsidiaries segments business geographic areas see information segments business geographic areas retirement pension plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care domestic retired employees dependents international employees covered government sponsored programs cost company significant retirement plan benefits primarily based employee 's compensation last three five years retirement number years service company 's objective funding domestic plans accumulate funds sufficient provide accrued benefits international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided certain countries united states funding pension plans common practice funding provides economic benefit consequently company several pension plans funded company fund retiree health care benefits advance right modify plans future net periodic benefit costs company 's defined benefit retirement plans benefit plans include following components table caption retirement plans benefit plans dollars millions c c c c c c service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial gainloss curtailments settlements net periodic benefit cost table net periodic income cost attributable domestic retirement plans million million million following tables provide weightedaverage assumptions used todevelop net periodic benefit cost actuarial present value projected benefit obligations table caption retirement plans benefit plans domestic benefit plans c c c c c c weighted average discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans weighted average discount rate expected longterm rate return plan assets rate increase compensation levels table health care cost trends united states projected annual rates individuals grading year beyond effect change assumed cost trends accumulated postretirement benefit obligation end would million increase million decrease effect service interest cost components net periodic postretirement benefit cost would million increase million decrease following tables set forth change benefit obligations change plan assets yearend company 's defined benefit retirement plans postretirement plans table caption dollars millions retirement plans benefit plans change benefit obligation c c c c benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial loss acquisitions curtailments settlements total benefits paid effect exchange rates benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year table amounts recognized company 's balance sheet consist following table caption retirement plans benefit plans dollars millions c c c c plan assets excess less projected benefit obligation unrecognized actuarial gains unrecognized prior service cost unrecognized net transition asset total recognized consolidated balance sheet book reserves prepaid benefits assets total recognized consolidated balance sheet table plans accumulated benefit obligations excess plan assets consist following table caption retirement plans benefit plans dollars millions c c c c accumulated benefit obligation projected benefit obligation plan assets fair value table marketable securities table caption december december dollars millions amortized unrealized unrealized estimated amortized unrealized unrealized estimated cost gains losses fair value cost gains losses fair value c c c c c c c c money market funds commercial paper time deposits government securities obligations asset backed securities bank notes corporate debt securities total current marketable securities government securities asset backed securities bank notes corporate debt securities investments held trust total noncurrent marketable securities table current marketable securities include billion billion classified cash equivalents balance sheet december december respectively financial instruments effective january company adopted sfas requiring allderivative instruments recorded balance sheet fair value january company recorded million netoftax cumulative effect transition adjustment gain accumulated comprehensive income recognize fair value derivative instruments designated cash flow hedges adjustment net earnings immaterial december balance deferred net gains derivatives included accumulated comprehensive income million tax amount company expects million reclassified earnings next months result transactions expected occur period amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative primary types underlying transactions cause amount accumulated comprehensive income affect net earnings primarily consist sales third parties maximum length time company hedging exposure variability future cash flows forecasted transactions months year ended december net impact hedges ' ineffectiveness company 's financial statements insignificant year ended december company recorded net gain million tax income expense net category consolidated statement earnings representing impact discontinuance cash flow hedges probable originally forecasted transactions occur end originally specified time period refer note disclosures movements accumulated comprehensive income concentration credit risk company invests excess cash deposits major banks throughout world high quality shortterm liquid money market instruments refer note additional information company policy making investments commercial institutions least equivalent credit rating investments generally mature within six months company incurred related losses company sells broad range products health care field countries world ongoing credit evaluations customers ' financial condition performed generally collateral required sales three distributors accounted total total company revenues company maintains reserves potential credit losses losses aggregate exceeded management 's expectations savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employee 's contributions consistent provisions plan heshe eligible us salaried plan onethird company match paid company stock employee stock ownership plan esop establish esop company loaned million esop trust purchase shares company stock open market exchange company received note balance recorded reduction shareowners ' equity total contributions plans million million million mergers acquisitions june johnson johnson alza corporation alza completed merger two companies transaction accounted poolingofinterests alza approximately million shares outstanding million fully diluted basis exchanged approximately million shares johnson johnson common stock diluted basis adjusted stock options convertible debt total number johnson johnson shares issued total approximately million shares holders alza common stock received share johnson johnson common stock valued per share alza researchbased pharmaceutical company leading drugdelivery technologies company applies delivery technologies develop pharmaceutical products enhanced therapeutic value portfolio many world 's leading pharmaceutical companies financial statements prepared give retroactive effect johnson johnson 's merger alza adjustments alza 's historical financial statements reflection income tax expense companies combined periods presented elimination transactions johnson johnson affiliate companies reclassification certain amounts conform johnson johnson presentation first quarter revenue net earnings johnson johnson prior merger alza billion billion respectively first quarter revenue net earnings alza included johnson johnson 's financial results million revenue million net earnings revenue net earnings johnson johnson prior merger alza billion billion respectively revenue billion billion respectively net earnings revenue net earnings alza included johnson johnson 's financial results million million respectively revenue million million respectively net earnings year ended december company incurred million pretax million tax costs associated alza merger costs included incomeexpense net certain businesses acquired billion million cash debt assumed approximately million shares company 's common stock issuable treasury valued billion acquisitions accounted purchase method accordingly results operations included accompanying consolidated financial statements respective dates acquisition acquisitions included inverness medical technology supplier lifescan 's electrochemical products blood glucose monitoring following spinoff nondiabetes businesses heartport company develops manufactures products less invasive open chest minimally invasive heart operations including stopped heart beating heart procedures teramed inc earlystage medical device company developing endovascular stentgraft systems minimally invasive treatment abdominal aortic aneurysms peripheral occlusive disease babycentercom internet content commerce site devoted supporting community expectant new mothers viactiv product line chewable calcium supplement mead johnson nutritionals division bristolmyers squibb inverness medical technology acquired enhance control primary supplier lifescan blood glucose monitoring products allow achievement operational synergies acquisition also provides key technology development future products preliminary purchase price allocation includes current assets million property plant equipment million current liabilities million deferred tax liabilities million long term debt million goodwill intangible assets acquired included million patents technology amortized period years less annual amortization million per year goodwill million accordance sfas goodwill intangible assets goodwill amortized deductible tax purposes approximately million identified value inprocess research development iprd associated inverness medical technology teramed inc acquisitions iprd charge primarily related inverness projects minimally invasive testing continuous monitoring insulin delivery value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factors ranging discount rate used pro forma information provided since impact acquisitions material effect company 's results operations cash flows financial position certain businesses acquired million million cash debt assumed approximately million shares company 's common stock issued treasury valued million acquisitions accounted purchase method accordingly results operations included accompanying consolidated financial statements respective dates acquisitions acquisitions included crescendo company formed alza purpose selecting developing commercializing human pharmaceutical products innovasive devices company manufactures sells devices sports medicine surgery soft tissue injuries atrionix inc developmentstage company whose primary product pulmonary ablation catheter treatment atrial fibrillation medtrex company develops manufactures electrosurgical generators disposable products st joseph aspirin business iprd writeoff associated atrionix inc alza 's crescendo acquisition million iprd charge primarily related atrionix project design catheter system used procedure blocks electrical impulses originating pulmonary veins cause atrial fibrillation value iprd calculated assistance third party appraiser using cash flow projection discounted risk inherent project discount rate used divestitures material effect company 's results operations cash flows financial position legal proceedings company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered reserves established selfinsurance program commercially available excess liability insurance one group cases company concerns janssen pharmaceutica product propulsid withdrawn general sale restricted limited use wake publicity events lawsuits comprising claims named individuals filed janssen wholly owned subsidiary company company regarding propulsid state federal courts across country approximately plaintiffs claim taken propulsid rest derivative plaintiffs spouses claims filed patients died use propulsid significant number cases also seek certification class actions actions accuse janssen company inadequately testing warning drug 's side effects promoting offlabel use overpromotion actions seek substantial compensatory punitive damages addition janssen company entered agreements various plaintiffs ' counsel halting running statutes limitations respect potential claims significant number individuals attorneys evaluate whether sue janssen company behalf september first plaintiffs rankin case comprises claims plaintiffs went trial state court claiborne county mississippi jury returned compensatory damage verdicts plaintiff amount million total million trial judge thereafter dismissed claims punitive damages janssen company believe verdicts insupportable reduced post trial motions reversed appeal view janssen company proof trial demonstrated none plaintiffs injured propulsid basis liability existed respect various propulsid actions janssen company dispute claims lawsuits vigorously defending except judgement settlement appropriate janssen company believe adequate self commercially available excess insurance respect cases company 's ortho biotech subsidiary party arbitration proceeding filed amgen ortho biotech 's licensor us nondialysis rights procriteprex amgen seeks terminate ortho biotech 's us license rights collect substantial damages based alleged deliberate procriteprex sales ortho biotech early 's amgen 's reserved dialysis market company believes basis exists terminating ortho biotech 's us license rights obtaining damages vigorously contesting amgen 's claims however ortho biotech 's us license rights procriteprex material company thus unfavorable outcome termination issue could material adverse effect company 's consolidated results operations cash flows financial position arbitration began january expected conclude april arbitrator 's decision follow submission posthearing briefs sides company lifescan subsidiary defendants several class actions filed federal state courts california alleged purchasers surestep blood glucose meters stripssuffered economic harm products contained undisclosed defects late lifescan pleaded guilty federal court three misdemeanors paid total million fines civil costs resolve investigation related alleged defects december actions settled settlement preliminarily approved federal district court settlement accounted company material patent infringement actions tried delaware federal court late cordis johnson johnson company obtained verdicts infringement patent validity damage awards boston scientific corporation medtronic ave inc based number cordis coronary stent patents december jury damage action boston scientific returned verdict million december jury medtronic ave action returned verdict million sums represent lost profit reasonable royalty damages compensate cordis infringement include pre post judgment interest february hearing held claims boston scientific medtronic ave patents issue unenforceable owing alleged inequitable conduct patent office post trial motions appeals federal circuit court appeals follow judgments likely paid proceedings run course furthermore since amount damages company may receive quantified legal process complete gain recorded financial statements either awards company also involved number patent trademark lawsuits incidental business company believes proceedings except noted would material adverse effect results operations cash flows financial position earnings per share following reconciliation basic net earnings per share diluted net earnings per share years ended december december january table caption shares millions c c c basic earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted earnings per share table diluted earnings per share calculation includes dilution effect convertible debt decrease interest expense million million million tax years respectively diluted earnings per share excludes million shares million shares million shares options year respectively exercise price options greater average market value resulting antidilutive effect diluted earnings per share capital treasury stock changes treasury stock table caption dollars millions except treasury stocknumber shares thousands shares amount c c balance january employee compensation stock option plans repurchase common stock business combinations balance january employee compensation stock option plans conversion subordinated debentures repurchase common stock business combinations balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock business combinations balance december table shares common stock authorized issued shares end shares end shares end selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized table caption dollars millions first second third fourth first second third fourth except per share amounts quarter quarter quarter quarter quarter quarter quarter quarter c c c c c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share table second quarter includes tax charge million relating alza merger costs third quarter includes tax charge million relating alza merger costs fourth quarter includes tax charge million relating inprocess research development iprd costs fourth quarter also includes tax charge million relating lifescan class action settlement fourth quarter includes tax charge million relating iprd costs restructuring gains fourth quarter also includes tax charge million relating federal government investigation lifescan 's surestep blood glucose meter report management management johnson johnson responsible integrity objectivity accompanying financial statements related information statements prepared conformity accounting principles generally accepted united states america include amounts based best judgments due consideration given materiality management maintains system internal accounting controls monitored corporate staff professionally trained internal auditors travel worldwide system designed provide reasonable assurance reasonable cost assets safeguarded transactions events recorded properly company organized principle decentralized management appropriate control measures also evidenced welldefined organizational responsibilities management selection development evaluation processes communicative techniques financial planning reporting systems formalized procedures always policy practice company conduct affairs ethically socially responsible manner responsibility characterized reflected company 's credo policy business conduct distributed throughout company management maintains systematic program ensure compliance policies pricewaterhousecoopers llp company 's independent auditor engaged audit financial statements pricewaterhousecoopers llp maintains understanding internal controls conducts tests auditing procedures considered necessary circumstances express opinion report follows audit committee board directors composed solely outside directors meets periodically independent auditor management internal auditors review work confirm properly discharging responsibilities addition independent auditor general counsel vice president internal audit free meet audit committee without presence management discuss results work observations adequacy internal financial controls quality financial reporting relevant matters ralph larsen robert j darretta ralph larsen robert j darretta chairman board directors vice president finance chief executive officer chief financial officer independent auditor 's report shareowners board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings consolidated statements equity consolidated statements cash flows present fairly material respects financial position johnson johnson subsidiaries december december results operations cashflows three years period ended december conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecoopers llp new york new york january segments business johnson johnson subsidiaries table caption sales customers dollars millions c c c consumer domestic international total pharmaceutical domestic international total medical devices diagnostics domestic international total worldwide total table table caption operating profit identifiable assets dollars millions c c c c c c consumer pharmaceutical medical devices diagnostics segments total expenses allocated segments general corporate worldwide total table table caption additions property depreciation plant equipment amortization dollars millions c c c c c c consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total table table caption geographic areas sales customers longlived assets dollars millions c c c c c c united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total table see management 's discussion analysis pages description segments company business export sales intersegment sales significant sales three distributors accounted total revenues sales concentrated pharmaceutical segment amounts allocated segments include interest incomeexpense minority interest general corporate income expense general corporate includes primarily cash marketable securities includes million alza merger costs pharmaceutical segment million inprocess research development iprd million class action settlement medical devices diagnostics segment includes restructuring gains million consumer segment million million restructuring gains net iprd charges pharmaceutical medical devices diagnostics segments respectively summary operations statistical data johnson johnson subsidiaries table caption dollars millions except per share figures c c c c c sales customers domestic sales customers international total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized expense net special charges earnings provision taxes income provision taxes income earnings cumulative effect accounting changes cumulative effect accounting changes net tax net earnings percent sales customers diluted net earnings per share common stock percent return average shareowners ' equity percent increase decrease previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense total tax expense per share supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareowners ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table table caption dollars millions except per share figures c c c c c c sales customers domestic sales customers international total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized expense net special charges earnings provision taxes income provision taxes income earnings cumulative effect accounting changes cumulative effect accounting changes net tax net earnings percent sales customers diluted net earnings per share common stock percent return average shareowners ' equity percent increase decrease previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense total tax expense per share supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareowners ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table adjusted reflect twoforone stock split excluding cumulative effect accounting changes million earnings percent sales customers accounting changes earnings per share accounting change earnings percent return average shareowners ' equity accounting changes diluted net earnings per share percent increase prior year accounting changes diluted net earnings per share increase prior year excluding special inprocess research development charges diluted net earnings per share special charges diluted net earnings per share increase prior year special charges earnings percent sales customers special charges diluted net earnings per share special charges percent return average shareowners ' equity special charges diluted net earnings per share increase prior year special charges cost products sold includes million inventory writeoffs restructuring diluted net earnings per share special charges excluding special charges diluted net earnings per share percent increase prior year diluted net earnings per share special charges excluding special charges diluted net earnings per share increase prior year diluted net earnings per share special charges excluding special charges diluted net earnings per share increase prior year periods adjusted include effects alza merger net interest income also included cost materials services category includes taxes income payroll property business taxes per share data calculated using average basic shares text document document typeex sequence filenameyextxt descriptionsubsidiaries text exhibit subsidiaries johnson johnson new jersey corporation domestic international subsidiaries shown certain domestic subsidiaries international subsidiaries named significant aggregate johnson johnson parent table caption jurisdiction name subsidiary organization c domestic subsidiaries alza corporation delaware alza land management inc delaware angioguard inc delaware biosense webster inc california canam care corporation new york centocor inc pennsylvania codman shurtleff inc new jersey cordis corporation florida cordis international corporation delaware crescendo pharmaceuticals corporation delaware depuy inc delaware depuy acromed inc ohio depuy acromed sales limited partnership massachusetts depuy finance llc delaware depuy orthopaedics inc indiana depuy orthopaedic technology inc delaware diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware heartport inc delaware independence technology llc new jersey innovasive devices inc massachusetts janssen finance company florida janssen inc delaware janssen ortho llc delaware janssen pharmaceutica inc pennsylvania janssen pharmaceutica products lp new jersey janssen products inc delaware johnson johnson consumer companies inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceuticals co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development new jersey llc table table caption jurisdiction name subsidiary organization c johnson johnson professional co pr inc delaware johnson johnson services inc new jerseyjohnson johnson vision care inc florida joint medical products corporation delaware jjhc inc delaware lifescan inc california lifescan llc delaware mcneilppc inc new jersey ndc investment corporation delaware neutrogena corporation delaware noramco inc georgia omj pharmaceuticals inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co florida orthomcneil pharmaceutical inc delaware teramed corporation delaware tylenol company new jersey therakos inc florida winthorpe valentine inc delaware international subsidiaries abello farmacia sl italy alza ireland limited ireland apsis france centra medicamenta otc srl italy cilag ag switzerland cilag ag international switzerland cilag de mexico sa de cv mexico cilag farmaceutica ltda brazil cilag holding ag switzerland cordis europa nv netherlands cordis medizinische apparate gmbh germany cordis de mexico sa de cv mexico cordis sa france cordis sarl switzerland depuy bioland sa france depuy france sa france depuy international ltd united kingdom depuy intl holdings ltd united kingdom depuy ireland limited ireland depuy japan kk japan depuy orthopadie gmbh germany depuy orthopedie sa france ethicon beteiligungs gesellschaft mbh germany table table caption jurisdiction name subsidiary organization c ethicon endosurgery europe gmbh germany ethicon gmbh germany ethicon ireland limited ireland ethicon limited scotland ethicon sas france ethicon spa italy ethnor proprietary limited south africa greiter ag switzerland greiter international ag switzerland impulse dynamics ireland limited ireland inverness medical limited scotland janssen animal health bvba belgium janssencilag norway janssencilag ab sweden janssencilag ag switzerland janssencilag denmark janssencilag bv netherlands janssencilag egypt ltd egypt janssencilag ca venezuela janssencilag farmaceutica ltda brazil janssencilag farmaceutica ltda portugal janssencilag farmaceutica sa argentina janssencilag ltd united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austriajanssencilag pty limited australia janssencilag sa spain janssencilag sa france janssencilag spa italy janssen farmaceutica sa de cv mexico janssencilag gmbh germany janssencilag international nv belgium janssen international cv belgium janssen korea ltd korea janssen ortho inc canada janssen pharmaceutica limited thailand janssen pharmaceutica nv belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical limited ireland jc healthcare ltd israel jhc nederland bv netherlands jjmsd consumer pharmaceuticals sas france johnson johnson ag switzerland johnson johnson denmark table table caption jurisdiction name subsidiary organization c johnson johnson sa de cv mexico johnson johnson de argentina sace argentina johnson johnson china investment co ltd china johnson johnson china ltd china johnson johnson consumer france sas france johnson johnson consumer nvsa belgium johnson johnson de colombia sa colombia johnson johnson del ecuador sa ecuador johnson johnson egypt sae egypt johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gmbh germany johnson johnson gesellschaft mbh austria johnson johnson hellas sa greece johnson johnson holding ab sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson industria e comercio ltda brazil johnson johnson international financial services ireland company johnson johnson international sa france johnson johnson investments limited united kingdom johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson kft hungary johnson johnson kk japan johnson johnson korea ltd korea johnson johnson lda portugal johnson johnson ltd united kingdom johnson johnson limited india johnson johnson msd consumer pharmaceuticals sas france johnson johnson management ltd united kingdom johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical gmbh austria johnson johnson medical kk japan johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nvsa belgium johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson morocco sa morocco johnson johnson new zealand limited new zealand johnson johnson pacific pty ltd australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines table tablecaption jurisdiction name subsidiary organization c johnson johnson poland sp z oo poland johnson johnson private limited zimbabwe johnson johnson products inc canada johnson johnson produtos profissionais ltda brazil johnson johnson professional products proprietary south africa ltd johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty limited australia johnson johnson sa de cv mexico johnson johnson sa spain johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson spolsro czech republic johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson de venezuela sa venezuela johnson johnson vision products ab sweden johnson johnson vision products ireland ltd ireland johnson johnson zambia limited zambia laboratoires martin johnson johnson msd sas france laboratoires polive snc france lifescan canada ltd canada mcneil consumer nutritionals europe switzerland medos sa switzerland neutrogena limited england neutrogena provence sarl france omj ireland limited ireland omj manufacturing ltd ireland orthoclinical diagnostics european support center france orthoclinical diagnostics gmbh germany orthoclinical diagnostics kk japan orthoclinical diagnostics united kingdom orthoclinical diagnostics sa spain orthoclinical diagnostics nv belgium orthoclinical diagnostics sa france orthoclinical diagnostics spa italy pharma argentina sa argentina pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china shanghai johnson johnson ltd china surgikos sa de cv mexico tasmanian alkaloids pty ltd australia rw johnson pharmaceutical research institute switzerland vania expansion snc france woelm pharma gmbh co germany xianjanssen pharmaceutical limited china table text document document typeex sequence filenameyextxt descriptionconsent independent accountants text exhibit consent independent accountants hereby consent incorporation reference registration statements johnson johnson form file form file form file related prospectuses report dated january relating audit financial statements johnson johnson subsidiaries december december three years period ended december appears annual report shareowners incorporated annual report also consent incorporation reference report dated january relating financial statement schedule appears pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york march text document document typeexb sequence filenameyexbtxt descriptioncautionary statement text exhibit b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company assumes obligation update forwardlooking statements result new information future events developments important factors could cause company 's actual results differ company 's expectations forwardlooking statements follows economic factors including inflation fluctuations interest rates foreign currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors challenges competitors company 's patents domestic foreign health care changes resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment government laws regulations relating sales promotion reimbursement pricing generally government laws regulations affecting domestic foreign operations including relating trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights competition research involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important company 's success areas business difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states abroad gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization productsignificant litigation adverse company including product liability claims patent infringement claims antitrust claims well arbitration proceeding filed amgen terminate us license rights product efficacy safety concerns resulting product recalls regulatory action part fda foreign counterparts declining sales impact business combinations including acquisitions divestitures internally company externally pharmaceutical health care industries issuance new revised accounting standards american institute certified public accountants financial accounting standards board securities exchange commission foregoing list sets forth many factors could impact upon company 's ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act text document secdocument end privacyenhanced message